Condition: Narcolepsy Type 1 (NT1) · Narcolepsy With Cataplexy · Sponsor: Takeda
The main aim of this study is to assess how effective TAK-861 is for treating narcolepsy type 1 and if this effect is maintained over time. Participants will take TAK-861 for a few months and if they meet certain criteria, they will be randomly assigned (by chance, like flipping a coin) to continue taking TAK-861 or take placebo (fake medicine) for up to 4 weeks to see if their narcolepsy symptoms return.
This description comes directly from the study's public registry record.
Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com
Always discuss trial participation with your own doctor first.
| Takeda Site 15 | Redwood City, California, United States | Recruiting |
| Takeda Site 19 | Brandon, Florida, United States | Recruiting |
| Takeda Site 22 | Miami, Florida, United States | Recruiting |
| Takeda Site 23 | Southfield, Michigan, United States | Recruiting |
| Takeda Site 20 | Middletown, New Jersey, United States | Recruiting |
| Takeda Site 24 | Durham, North Carolina, United States | Recruiting |
| Takeda Site 25 | Winston-Salem, North Carolina, United States | Recruiting |
| Takeda Site 16 | Cincinnati, Ohio, United States | Recruiting |
| Takeda Site 18 | Cleveland, Ohio, United States | Recruiting |
| Takeda Site 17 | Columbia, South Carolina, United States | Recruiting |
| Takeda Site 21 | Austin, Texas, United States | Recruiting |
| Takeda Site 1 | Montpellier, France | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07363720